Duchenne Muscular Dystrophy Therapeutic Approaches through Phytochemicals Exposure to Induce Exon- Skipping and Upregulation of Utrophin USM – DMD Group.

Slides:



Advertisements
Similar presentations
Medical Genetics 2 Prof Duncan Shaw.
Advertisements

Chromosome Disorders. Classification of genetic disorders  Single-gene disorders (2%)  Chromosome disorders (
Marine Biotechnology Student name: Hagay Livne I.D:
Genetics and Health Jennifer Eyvindson Epi 6181 November 2006.
It Affects… Cardiac Muscle Skeletal Muscle Nervous System increase in serum Creatine Kinase which is a marker for muscle damage Schizophrenia or related.
Philip Ord Isaac Lalich DUCHENNE MUSCULAR DYSTROPHY (DMD)
By: Kristina Feeley MUSCULAR DYSTROPHY  Muscular Dystrophy is a disease in which the muscles become weak over time.  People with md have missing information.
Duchenne Muscular Dystrophy
1of 20 Practical and Ethical Challenges in Molecular Diagnostic Services of Genetic Disorders - Experiences of Universiti Sains Malaysia Teguh Haryo Sasongko,
Control of Gene Expression Eukaryotes. Eukaryotic Gene Expression Some genes are expressed in all cells all the time. These so-called housekeeping genes.
By: Logan Gillings, Reyes E. Cause Of Disease  Is a genetic disorder that causes progressive muscle weakness as individual muscle cells die.  An absence.
How does the functions of the muscles effect Muscular Dystrophy?? And what could be done to increase muscle function?? MY QUESTION(S):
Cells Treated with serial diluted compound and incubated for 24 hours Evaluating the Effects of Small Molecule Drugs on Correcting Alternative Splicing.
(DMD) Duchenne Muscular Dystrophy. History of DMD It was first described by a french neurologist named Guillaume Benjamin Amand Duchenne in Previous.
Molecular Basis for Relationship between Genotype and Phenotype DNA RNA protein genotype function organism phenotype DNA sequence amino acid sequence transcription.
Center for Integrated Animal Genomics Research Experience in Molecular Biotechnology & Genomics Summer 2010 PGC1α over-expression rescues skeletal muscle.
Muscular Dystrophy Michael & Mhyke. Symptoms The symptoms are progressive weakening, breaking down of muscle fibers, drooling, eyelids dropping, frequent.
Computational biology of cancer cell pathways Modelling of cancer cell function and response to therapy.
Figure 17.0 Ribosome. Figure 17.1 Beadle and Tatum’s evidence for the one gene-one enzyme hypothesis.
Chapter 12.7 Examples of X-Linked Inheritance Patterns AP Biology Fall 2010.
Chapter 17 – From Gene to Protein 1909 – Garrod : First to suggest that genes dictate phenotypes through enzymes that catalyze specific chemical processes.
Complexities of Gene Expression Cells have regulated, complex systems –Not all genes are expressed in every cell –Many genes are not expressed all of.
DNA and Mutations. Mutation Facts #1-5 Write down five facts about mutations as we go through the following videoclips Video 1 Video 2 – Repair Video.
Duchenne Muscular Dystrophy By Mason Bross A.K.A. Pseudohypertrophic Muscular Dystrophy A.K.A. Duchenne and Becker muscular dystrophy.
Valproic acid in SMA Brunhilde Wirth Institute of Human Genetics University of Cologne, Germany.
Promising new drug candidates for Duchenne Muscular Dystrophy Dominic Wells Department of Comparative Biomedical Sciences Royal Veterinary College London.
Exon Duplication and 5’ mutations in the DMD gene Nicolas Wein, PhD Flanigan Lab Center for Gene Therapy Nationwide Children’s Hospital Columbus, OH, USA.
S O D I U M a n d C H L O R I D E C H A N N E L S 2  :2  :1   aminobutyric acid (GABA) receptor/channel ligand gated Cl - channel EtOH is an agonist.
Date:01 December 2015 Time:6:30 – 9:30 pm Location:Emory University Presentation Room 308 Speakers:Dr. John Richardson National DMD Assoc. President Got.
Genes that are located on the sex chromosomes are sex-linked genes. In mammals, individuals with two X chromosomes, an XX genotype, are females. Individuals.
Duchenne Muscular Dystrophy By: Andrea Ortega. Chromosome Graphic.
Duchenne Muscular Dystrophy By: Callia Ricozzi. What is Muscular Dystrophy?  The deterioration of the muscles  Dystrophin not made  gene mutation 
Research and Development Name: Julie Long Student Number: C Course Code: DT204.2.
DNA and Mutations. 5 Mutation Facts Write down five facts about mutations as we go through the following videoclips Video 1 Video 2 – Repair Video 3 –
D uchenne M uscular D ystrophy - GENETICS - The Cause and Cure By: Chaz B.
What we are learning about Alzheimer’s disease genetics Bryan J. Traynor.
The Medical Genetics of Dystrophinopathies 张咸宁 Tel : ; Office: C303, Teaching Building 2015/11.
Date of download: 7/8/2016 Copyright © 2016 American Medical Association. All rights reserved. From: A Renaissance for Antisense Oligonucleotide Drugs.
Lecture 2 Topic 1.
Gunn Abilities United Club. Muscular Dystrophy February 2014.
Genetic Disorder Cluster Muscular Dystrophy Drug Development Pipeline Review, 2017 Published: May 2017 Single User PDF: US$ 3995 Order this report by calling.
KEY AREA 4: Genes and Proteins in Health & Disease
Full length dystrophin gene Microgene for dystrophin
Duchenne muscular dystrophy (DMD)
Chapter 18: Chromosome A Cell Nucleus 149, aa Cytoplasm
Molecular Therapy - Nucleic Acids
Gene Hunting: Design and statistics
Relationship between Genotype and Phenotype
Relationship between Genotype and Phenotype
Relationship between Genotype and Phenotype
Combination of Multiple Ligation-Dependent Probe Amplification and Illumina MiSeq Amplicon Sequencing for TSC1/TSC2 Gene Analyses in Patients with Tuberous.
COX-1 and known variants.
281. Rapid Generation of Induced Pluripotent Stem Cells (iPSCs) from the Urine of a Patient with Duchenne Muscular Dystrophy    Molecular Therapy  Volume.
Thomas W. Prior, Scott J. Bridgeman 
Relationship between Genotype and Phenotype
Genetics and Information
Combination of Multiple Ligation-Dependent Probe Amplification and Illumina MiSeq Amplicon Sequencing for TSC1/TSC2 Gene Analyses in Patients with Tuberous.
Duchenne Muscular Dystrophy
Chemical Genetics and Orphan Genetic Diseases
Figure 2 Pathophysiological mechanisms in LGMD
Schematic depiction of the effect of different types of Duchenne muscular dystrophy (DMD)-causing mutations on the dystrophin transcript. Schematic depiction.
Annemieke Aartsma-Rus, Anneke A. M. Janson, Wendy E
Volume 14, Issue 3, Pages (September 2006)
Relationship between Genotype and Phenotype
Multiple-exon skipping.
Duchenne Muscular Dystrophy Models Show Their Age
Volume 20, Issue 11, Pages (November 2012)
Combination of Multiple Ligation-Dependent Probe Amplification and Illumina MiSeq Amplicon Sequencing for TSC1/TSC2 Gene Analyses in Patients with Tuberous.
Figure 1 ASO functions ASO functions Target mRNA fates depending on ASO mechanism of action that is determined by where the ASO is targeted and by ASO.
Presentation transcript:

Duchenne Muscular Dystrophy Therapeutic Approaches through Phytochemicals Exposure to Induce Exon- Skipping and Upregulation of Utrophin USM – DMD Group Presented at the Transdisciplinary Research Seminar USM Health Campus, 27 July 2010

Workshop on Current Approaches in Gene Therapy for Duchenne Muscular Dystrophy and Beta-Thalassemia USM Pulau Pinang, 29 – 30 June 2010

DMD; The Burden Commonest Neuromuscular Genetic Disorder Most Severe form of MD Progressive Muscle Weakness 1:3500 males Reduced Life Expectancy and Quality of Life Wheelchair-Bound NO CURE!!!

DMD; The Gene Dystrophin gene (3000 kb) Dystrophin mRNA (14 kb, 79 exons) X Chromosome

DMD; The Genetic Basis

DMD; The molecular pathogenesis

Pathophysiology of DMD Natural Products Phenotype- Genotype correlation study Targeting the mRNA splicing Upregulating Utrophin The effect on MDX model Compensatory mechanism dystroglycan- associated protein complexes Other molecular pathways DMD: FROM BENCH to BEDSIDE STUDIES

Reading Frame Rule DMD and BMD Dystrophin Deletion Ex.45 (176nt)  DMD Dystrophin Deletion Ex (1104nt)  BMD THE BOY MAY HIT AND RUN (NORMAL)(BMD) THE BOY MAY HIT AND RUN (DMD) THE BOYMA YHI TAN DRU N

Treatment of DMD by Exon-Skipping THE Takeshima et al., 2006 YMA Y HI T AN D RU N BO HIT AND RUN ?

Compounds Inducing Splicing Alternation Histone Deacetylase Inhibitors (sodium butyrate, valproic acid, phenylbutyrate, etc…) Kinase Inhibitors (aclarubicin, camptotechin, isodiospyrin, lithium chloride, etc…) Phospatase Inhibitors (sodium orthovanadate, tautomycin, cantharidin, etc…) cAMP Pathway (indoprofen, salbutamol) SR Protein-Protein Interactions (isoquinoline) Coupling of Transcription and Splicing (dexamethazone, dihydroepiandrosterone, steroid hormones) Ion-channels and Electrochemical Gradients (amiloride, glutamate) Unknown Role (hydroxyurea, kinetin, curcumin, etoposide, etc…) European Alternative Splicing Network (

DMD and Utrophin

Utrophin ? 6q24.2

Compounds Inducing Utrophin Upregulation Transcriptional Activators Heregulin, Modulation of calcineurin-NFAT signalling, L-Arginine

What about compounds from our own backyards ?

Seeking Collaborators Botanist (FRIM) “Pathway Studio” (Centre for Chemical Biology, USM) Chemist Pharmacist; Dr. Habibah Abdul Wahab Biologist Prof. Syed Mohsin Syed Sahil Jamalullail

USM-DMD Group (so far…) Teguh Haryo Sasongko, Abdul Aziz Mohd. Yusoff, Muzaimi Mustapha, Ong Ming Thong, Sarina Sulong, Chia Boon Hock, Khairani Idah Mokhtar, Wan Rohani Wan Taib, Rowani Mohd. Rawi, Rani Abdulqawee, Khaleed, Zilfalil Alwi, Zabidi Hussin, Shaharum Shamsuddin, Md. Azman Seeni, Badrul Hisham Yahaya